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al., 2011), and cardiac tissue (Morritt et al., 2007). While regenera-
tion of any of these tissues in a human model would have important
clinical uses, the inability to control the internal structure of the re-
generated tissues still limits TEC from regenerating fully functioning
non-endocrine organs. For example, Forster and colleagues cultured
liver progenitor cells (LPCs) to form three-dimensional clustersOxygen delivery is the greatest limiting factor to large-volume tissue
engineering. Regenerating post-mastectomy breast tissue requires
avascular adipose tissue to be transferred as thin “micro-ribbons” to
avoid central necrosis (Khouri et al., 2014). Similarly, scaffold-based
constructs lack the central vascularity necessary for large-volume tissue
regeneration (Post et al., 2013). The tissue engineering chamber (TEC)
induces the recipient bed to regenerate fully vascularized tissue
in vivo, thereby providing the oxygen delivery necessary to support
large-scale tissue regeneration. In the above article (Morrison et al.,
2016), Morrison and colleagues describe the ﬁrst successful use of TEC
to generate well-vascularized, large-volume human adipose tissue
in vivo. While TEC-based constructs do not have the same ability as
scaffold-based constructs to control the internal structures of regenerat-
ed tissues, they still have potential utility in certain clinical scenarios.
Adipose tissue is an ideal model for in vivo soft tissue regeneration
because its function does not depend on tissue microanatomy or
organ gross anatomy. However, adipose tissue regeneration with TEC
lacksmajor clinical utility because, with proper technique and recipient
site preparation, large-volume autogenous adipose tissue transfers can
already safely be performed for reconstruction of breasts and other
soft tissue defects (Khouri et al., 2015, 2013). Alternatively, endocrine
tissue regeneration has no current clinical substitute, and endocrine
functions do not depend on anatomy; a thin sheet of functioning endo-
crine tissue placed anywhere in the body could replace damaged native
tissue. Morrison contributed to a study that transplanted pancreatic is-
lets into TECs in diabetic mice, which resulted in signiﬁcantly improved
glycemic control (Hussey et al., 2009). Reproducing these ﬁndings in
humans would have an enormous clinical impact given the prevalence
of diabetes mellitus type 1 and cases of diabetes mellitus type 2
that require exogenous insulin.
Morrison has also contributed to other rodent TEC studies that
have successfully regenerated large volumes of functioning pituitaryom.2016.03.032.
ical School, 1113 Freesia Ct, Ann
i).
. This is an open access article under(Lepore et al., 2007), thymic (Seach et al., 2010), hepatic (Forster et
within a matrix before implantation in a chronic liver injury model
using TEC (Forster et al., 2011). LPCs differentiated into hepatocytes
with the ability to perform hepatocyte-speciﬁc metabolism and bio-
synthesis but without the ductal drainage system necessary for
whole organ regeneration.
Whole organ regeneration would require the vascularity associated
with TEC and the internal anatomy associated with cell scaffold-based
constructs. An intricate combination of TEC and a cell-scaffold based
construct might create a solution; however, this concept seems well
ahead of our current capabilities given the widely varied results Morri-
son and colleagues obtained using TEC in humans.
Morrison and colleagues should be commended for their novel work.
While these ﬁndings cannot yet impact clinical practice, they should en-
courage researchers to continue making strides towards translating tis-
sue engineering breakthroughs to the clinical arena. TEC clearly has
great potential for regeneration of human tissues, but before advancing
any further, TEC must demonstrate the ability to consistently produce
predictable outcomes.
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